-
-
-
-
-
-
-
Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance
-
-
-
-
-
-
-
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance
-
-
-
-
-
-
-
Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares
-
-
-
-
-
-
-
Ironwood Pharmaceuticals Reports Strong Third Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance
-
-
-
-
-
-
-
Ironwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Bil
-
-
-
-
-
-
-
Ironwood Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2019 Results, Exceeding Full Year 2019 Guidance; Provides Full Year 2020 Guidance
-
-
-
-
-
-
-
Ironwood Pharmaceuticals Provides Second Quarter 2018 Investor Update
-
1,201,772 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


